Fermenta Biotech Ltd
Fermenta Biotech Ltd Q4 FY25 Results & Presentation Highlights: Revenue ₹143.7 Cr, PAT ₹33.3 Cr
Q4 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Fermenta Biotech Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q4 FY25 Revenue: ₹143.7 crore - Up 40% year-on-year (YoY) - Down 9% quarter-on-quarter (QoQ) - FY25 Revenue: ₹481.3 crore - Up 39% YoY - Human nutrition volume grew by 48% over FY24 - Animal nutrition volume grew by 24% over FY24 - No explicit forward-looking revenue or volume outlook stated in the presentation. Q4 FY25 EBITDA: ₹40.8 crore (up 280% YoY, down 26% QoQ) - Q4 FY25 Revenue: ₹143.7 crore (up 40% YoY, down 9% QoQ) - Q4 FY25 Profit After Tax (PAT): ₹33.3 crore (up ₹40.5 crore YoY, down 12% QoQ) - Margins: The presentation reports an EBITDA margin jump to 26% for FY25 (page 9), reflecting strong cost control and improved realizations.
From Fermenta Biotech Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY25 Revenue: ₹143.7 crore
- Up 40% year-on-year (YoY)
- Down 9% quarter-on-quarter (QoQ)
- FY25 Revenue: ₹481.3 crore
- Up 39% YoY
- Human nutrition volume grew by 48% over FY24
2 more points management made on revenue & sales performance
Profitability & Margins
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY25 capex was ₹22 crore, slightly increased from ₹19 crore in FY24 (Page 11).
- Validation batches completed for spray dried (SD) variant of Vitamin D3 100,000 IU/g powder for human nutrition; qualification ongoing with global customers and regulators (Page 5).
- Commercial scale production achieved for plant-based Vitamin D3 active ingredient using proprietary technology; validation batches for plant-based D3 oil and spray dried powder variants completed; qualification process ongoing with global customers and regulatory authorities (Page 5).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Fermenta Biotech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹122 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech Ltd's management said in earlier quarters
- Q4 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q2 FY22 earnings call →
- Q1 FY22 earnings call →
- Q1 FY22 earnings call →
- Q3 FY21 earnings call →
- Q2 FY21 earnings call →
- Q2 FY21 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Anuh Pharma Ltd (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare Ltd (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q4 FY25 investor presentation — and how it ranks against sector p
- Lincoln Pharmaceuticals Ltd (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 investor presenta
- Kopran Ltd (Q4 FY25)
1,372 Lakhs (~7.37% decline) . Key investor presentation takeaways from Kopran Ltd's Q4 FY25 investor presentation — and how it ranks against sector peers.
Frequently Asked Questions
What were Fermenta Biotech Ltd Q4 FY25 results?
Q4 FY25 Revenue: ₹143.7 crore - Up 40% year-on-year (YoY) - Down 9% quarter-on-quarter (QoQ) - FY25 Revenue: ₹481.3 crore - Up 39% YoY - Human nutrition volume grew by 48% over FY24 - Animal nutrition volume grew by 24% over FY24 - No explicit forward-looking revenue or volume outlook stated in the presentation. Q4 FY25 EBITDA: ₹40.8 crore (up 280% YoY, down 26% QoQ) - Q4 FY25 Revenue: ₹143.7 crore (up 40% YoY, down 9% QoQ) - Q4 FY25 Profit After Tax (PAT): ₹33.3 crore (up ₹40.5 crore YoY, down 12% QoQ) - Margins: The presentation reports an EBITDA margin jump to 26% for FY25 (page 9), reflecting strong cost control and improved realizations.
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 25.5 with a market cap of ₹1,395 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fermenta Biotech Ltd planning capital expenditure?
FY25 capex was ₹22 crore, slightly increased from ₹19 crore in FY24 (Page 11). - Validation batches completed for spray dried (SD) variant of Vitamin D3 100,000 IU/g powder for human nutrition; qualification ongoing with global customers and regulators (Page 5). - Commercial scale production achieved for plant-based Vitamin D3 active ingredient using proprietary technology; validation batches for plant-based D3 oil and spray dried powder variants completed; qualification process ongoing with global customers and regulatory authorities (Page 5). - No explicit mention of new plant construction, capacity expansion projects, or future timeline details in the presentation.
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.